Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function.

ABSTRACT:

Study question

Do genetic variations in the DNA damage response pathway modify the adverse effect of alkylating agents on ovarian function in female childhood cancer survivors (CCS)?

Summary answer

Female CCS carrying a common BR serine/threonine kinase 1 (BRSK1) gene variant appear to be at 2.5-fold increased odds of reduced ovarian function after treatment with high doses of alkylating chemotherapy.

What is known already

Female CCS show large inter-individual variability in the impact of DNA-damaging alkylating chemotherapy, given as treatment of childhood cancer, on adult ovarian function. Genetic variants in DNA repair genes affecting ovarian function might explain this variability.

Study design, size, duration

CCS for the discovery cohort were identified f

SUBMITTER: van der Kooi ALF 

PROVIDER: S-EPMC7970730 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature